ascopubs.org

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

Purpose Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in patients with ...
ascopubs.org

Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis

Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials VEGFR1 and VEGFR2 peptides were injected subcutaneously into ...
Nasdaq

Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and ...

For more information on the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH), please click here. The ATEV is an investigational product and has not been ...
KELOLAND News

Vascular Therapies Completes Enrollment in the ACCESS 2 Study, a Phase III Multinational Randomized Clinical Trial of the Sirolimus Eluting Collagen Implant (Sirogen) for the ...

CRESSKILL, NJ / ACCESSWIRE / August 5, 2024 / Vascular Therapies, a biotechnology company focused on improving vascular access outcomes in patients with kidney disease, today announced completion of ...